Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.

doi:10.1158/2159-8290.CD-20-0873

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.

Cancer discovery - 1 Mar 2021

Hong Aayoung, Piva Marco, Liu Sixue, Hugo Willy, Lomeli Shirley H, Zoete Vincent, Randolph Christopher E, Yang Zhentao, Wang Yan, Lee Jordan J, Lo Skylar J, Sun Lu, Vega-Crespo Agustin, Garcia Alejandro J, Shackelford David B, Dubinett Steven M, Scumpia Philip O, Byrum Stephanie D, Tackett Alan J, Donahue Timothy R, Michielin Olivier, Holmen Sheri L, Ribas Antoni, Moriceau Gatien, Lo Roger S

Abstract excerpt

MAPK targeting in cancer often fails due to MAPK reactivation. MEK inhibitor (MEKi) monotherapy provides limited clinical benefits but may serve as a foundation for combination therapies. Here, we showed that combining a type II RAF inhibitor (RAFi) with an allosteric MEKi durably prevents and overcomes acquired resistance among cancers with KRAS, NRAS, NF1, BRAF non-V600, and BRAF V600 mutations. Tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to GTP Phosphohydrolases

Share to Immunity, Cellular

Share to Lymphocytes, Tumor-Infiltrating

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Stability

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33318037
DOI: 10.1158/2159-8290.CD-20-0873
PMCID: PMC7933113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.PMID 33318037Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancerSemantic proximity Read ↗

The non-linearity of RAF-MEK signaling in dendritic cells.Semantic proximity Read ↗

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.Semantic proximity Read ↗

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.Semantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

ERK inhibition overcomes acquired resistance to MEK inhibitors.Semantic proximity Read ↗

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studiesSemantic proximity Read ↗

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytesSemantic proximity Read ↗

BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma.Semantic proximity Read ↗

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Semantic proximity Read ↗

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.